MedicineOncologyPharmacologyCancer PharmacologyChemotherapyOncology PharmacotherapyCombination Cancer TherapyLung CancerLung Cancer PharmacotherapyMalignant NeoplasmsOncology PharmacologyHistone Deacetylase TargetsNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPhase Ii InvestigationStudy Phase
Titan is developing AN-9 for the potential treatment of various cancers. AN-9 is a histone deacetylase inhibitor analog of butyric acid that causes apoptosis of cancer cells through signaling cellular differentiation. In March 2001, a phase I/II study involving patients with liver tumors was initiated. By November 2001, enrollment had been completed in a second phase II study of refractory non-small-cell lung cancer (NSCLC). In June 2003, Titan began enrollment for a phase IIb trial of AN-9 in combination with docetaxel in patients with NSCLC.